Achieve Life Sciences, Inc.
ACHVNASDAQHealthcare● Active
$5.48
+$0.35(+6.82%)
Market Cap$562571320
P/E Ratio—
52W High$6.15
52W Low$2
Achieve Life Sciences, Inc. (ACHV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACHV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.19
Est. -$0.30 · +36.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ACHV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.20 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.30 | -$0.19 | +36.7% | — | — | — |
| ▼ Q1 FY2026 | Mar 24, 2026 | -$0.27 | -$0.28 | -3.7% | — | — | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.24 | -$0.28 | -16.7% | — | — | — |
| — Q3 FY2025 | Aug 7, 2025 | -$0.37 | -$0.37 | +0.0% | — | — | — |
| — Q2 FY2025 | May 13, 2025 | -$0.37 | -$0.37 | +0.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 11, 2025 | -$0.30 | -$0.36 | -20.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.26 | -$0.36 | -38.5% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.30
EPS Surpr.
+36.7%
Revenue
—
Q1 FY2026
Mar 24, 2026Miss
EPS Actual
-$0.28
EPS Est.
-$0.27
EPS Surpr.
-3.7%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.24
EPS Surpr.
-16.7%
Revenue
—
Q3 FY2025
Aug 7, 2025
EPS Actual
-$0.37
EPS Est.
-$0.37
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.37
EPS Est.
-$0.37
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 11, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.30
EPS Surpr.
-20.0%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.36
EPS Est.
-$0.26
EPS Surpr.
-38.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.02 | $0.02 | $0.02 | 1 |
| Q3 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q1 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.17 | $-0.17 | $-0.16 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +36.7% | $5.59 | $5.99 | +7.16% |
| ▼ Q1 FY2026 | Mar 24, 2026 | -3.7% | $4.05 | $2.90 | -28.40% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -16.7% | $4.93 | $4.74 | -3.85% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +0.0% | $2.64 | $2.64 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $2.48 | $2.65 | +6.85% |
| ▼ Q1 FY2025 | Mar 11, 2025 | -20.0% | $3.06 | $2.92 | -4.58% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -38.5% | $5.12 | $5.00 | -2.34% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -13.6% | $4.34 | $4.36 | +0.46% |
Q2 FY2026+7.16%
Report Date
May 12, 2026
EPS Beat/Miss
+36.7%
Price Before
$5.59
Price After
$5.99
Q1 FY2026-28.40%
Report Date
Mar 24, 2026
EPS Beat/Miss
-3.7%
Price Before
$4.05
Price After
$2.90
Q4 FY2025-3.85%
Report Date
Nov 6, 2025
EPS Beat/Miss
-16.7%
Price Before
$4.93
Price After
$4.74
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.64
Price After
$2.64
Q2 FY2025+6.85%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.48
Price After
$2.65
Q1 FY2025-4.58%
Report Date
Mar 11, 2025
EPS Beat/Miss
-20.0%
Price Before
$3.06
Price After
$2.92
Q4 FY2024-2.34%
Report Date
Nov 7, 2024
EPS Beat/Miss
-38.5%
Price Before
$5.12
Price After
$5.00
Q3 FY2024+0.46%
Report Date
Aug 13, 2024
EPS Beat/Miss
-13.6%
Price Before
$4.34
Price After
$4.36
Avg Beat Reaction+4.67%
Avg Miss Reaction-7.74%
Beat Rate3 / 8 quarters
Largest Move-28.40% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACHV ends December
Achieve Life Sciences, Inc. (ACHV) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.30 by +36.7%. The next ACHV earnings date is expected around September 1, 2026.
Each quarter, investors track ACHV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACHV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACHV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACHV earnings · 5 questionsAchieve Life Sciences, Inc.'s next earnings report is expected around September 1, 2026. ACHV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACHV historically reports after market close (AMC).
ACHV earnings datewhen is ACHV earningsACHV next earnings datewhen does ACHV report earningsACHV earnings calendar
▸ Source: FMP · Achieve Life Sciences, Inc. SEC filings · US GAAP · Achieve Life Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026